Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Medicus Pharma Ltd ( (MDCX) ).
Medicus Pharma Ltd has submitted a Phase 2 clinical design to the UAE Department of Health to evaluate a non-invasive treatment for basal cell carcinoma of the skin. The study will involve 36 participants across four clinical sites in the UAE and aims to assess the efficacy of different doses of D-MNA, a compound previously tested for safety and tolerability.
More about Medicus Pharma Ltd
Medicus Pharma Ltd is a pharmaceutical company that focuses on developing non-invasive treatments for skin conditions. The company is listed on NASDAQ under the ticker MDCX and is involved in clinical research to advance its product offerings.
Average Trading Volume: 1,347
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: C$67.84M
Find detailed analytics on MDCX stock on TipRanks’ Stock Analysis page.